These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2007-005613-19 R-COMP 14 in elderly patients with high grade non-Hodgkin lymphoma bad-data
Ongoing 2008-001369-27 PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER not-yet-due
Completed, but no date 2008-002736-15 Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transpla... bad-data
Completed, but no date Terminated 2008-003828-38 Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years. bad-data
Ongoing 2009-014481-26 Treatment of brain metastases (MTSC) by Whole Brain Radiotherapy (WBRT) and temozolomide (TMZ) concomitant not-yet-due
Ongoing 2010-019139-36 RTaxot: Docetaxel-based concurrent chemo-hormono-radiation in high and very high-risk prostate cancer patients: a phase II multicenter trial not-yet-due
Ongoing 2011-000637-37 “AN OBSERVATIONAL STUDY ON THE MOLECULES INVOLVED IN THE INTRACELLULAR UPTAKE IN PATIENTS AFFECTED FROM CHRONIC MYELOID LEUKEMIA RECEIVING TIROSINE-KINASE INHIBITORS.” STUDIO DELLE MOLECOLE COINVOL... not-yet-due
Completed, but no date, and reported results 2011-001246-14 Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transpla... bad-data
Ongoing 2012-000334-19 Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML) Studio multicentrico di fase II con Citarabina a basse dosi ... not-yet-due